Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 17/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849058 | 1.00 | CCR1 (1.00) | CCR1SMN1; SMN2 | |
| SCHEMBL18781954 | 0.94 | CCR1 (0.88) | CCR1 | |
| SCHEMBL3843695 | 0.94 | CCR1 (0.88) | CCR1SMN1; SMN2 | |
| SCHEMBL3843689 | 0.94 | CCR1 (0.88) | CCR1SMN1; SMN2 | |
| SCHEMBL13375038 | 0.93 | CCR1 (0.87) | CCR1SMN1; SMN2 | |
| SCHEMBL18776054 | 0.91 | CCR1 (0.83) | CCR1SMN1; SMN2 | |
| SCHEMBL13375127 | 0.90 | CCR1 (0.81) | CCR1 | |
| SCHEMBL13375269 | 0.90 | CCR1 (0.81) | CCR1 | |
| SCHEMBL13375047 | 0.90 | CCR1 (0.81) | CCR1SMN1; SMN2 | |
| SCHEMBL13375004 | 0.90 | CCR1 (0.81) | CCR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017070431-A1 | USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM | MERRITT JAMES (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170112831-A1 | USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM | MERRITT JAMES (US) | 2017-04-27 | — | — | US | disclosed |
| US-8288371-B2 | Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation | PHARMACOPEIA, LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288371-B2 | Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation | PHARMACOPEIA, LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288371-B2 | Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation | PHARMACOPEIA, LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | PHARMACOPEIA, INC. (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093472-A1 | ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION | CCR1, CCR4, CCR3 | CCR1 1/4885SMN1; SMN2 2159/4885 |
| US-20170112831-A1 | USE OF CCR1 ANTAGONISTS AS A TREATMENT FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM | CCR1, CCR3, CCR4 | CCR1 1/4885SMN1; SMN2 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.